Caris Life Sciences Inc. (NASDAQ: CAI) has reported a remarkable fourth-quarter performance, leading to a surge in its stock price during Friday’s premarket trading. The company announced earnings of **$0.28** per share, significantly exceeding the consensus expectation of a **$0.03** loss. Additionally, sales for the quarter soared by **125%** year over year, reaching **$292.89 million**, far surpassing analyst forecasts of **$208.63 million**.
The substantial revenue growth was primarily driven by a **199%** increase in molecular profiling services, which generated **$282.1 million**. This success stemmed from a rise in clinical case volumes and improvements in average selling prices across therapy selection solutions. Caris processed approximately **52,700** clinical therapy selection cases during the quarter, marking a **20%** increase from the previous year, including around **44,150** MI Profile cases and **8,550** Caris Assure cases. The company achieved a gross margin of **75%**, reflecting an impressive improvement of about **2,000 basis points**.
Caris also reported a positive Adjusted EBITDA of **$106.1 million**, reversing a loss of **$23 million** from the previous year.
Future Projections and Operational Insights
Looking ahead, Caris Life Sciences projects fiscal 2026 sales between **$1 billion** and **$1.02 billion**, although this is below the consensus estimate of **$1.198 billion**. The company anticipates operating expenses to range from **$590 million** to **$595 million**, representing a **19% to 20%** increase driven by commercial expansion and heightened pipeline trial activities. Despite these rising costs, Caris expects to maintain positive Free Cash Flow and Adjusted EBITDA.
In addition to financial results, Caris Life Sciences has made notable advancements in its multi-cancer early detection test, **Caris Detect**. This test employs Whole Genome Sequencing to enhance early cancer detection capabilities. The interim readout from the Achieve 1 study demonstrates Caris Detect’s superiority in sensitivity and specificity compared to traditional detection methods. The study analyzed approximately **1,505** samples from undiagnosed patients, reinforcing the upcoming launch of Caris Detect. Further results from the blinded validation phase are expected to be released later in the first quarter of **2026**.
Caris has also processed over **one million** cases, generating more than **50 billion** molecular markers, which underlines the robust data foundation that supports its AI-driven cancer detection efforts.
Analyst Ratings and Market Response
Analysts have responded positively to Caris Life Sciences’ performance. The stock currently holds a Buy Rating, with an average price target of **$33.63**. Recent ratings include Baird’s initiation with an Outperform rating and a **$26.00** target on **February 17, 2026**, and Canaccord Genuity’s Hold rating with an increased target of **$30.00** as of **December 22, 2025**.
On Friday, shares of Caris Life Sciences experienced a **20.43%** increase, trading at **$23.17** during premarket hours, according to data from Benzinga Pro.
The company’s compelling financial performance and innovative advancements in cancer detection technology position it as a significant player in the healthcare sector, garnering attention from investors and analysts alike.
